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licenses/by-nc-nd/4.0/).Rationale & Objective: Surrogate outcomes for
end-stage kidney disease often assume linear
changes, which may not reflect true estimated
glomerular filtration rate (eGFR) trajectories.
This study’s objective was to characterize
nonlinear eGFR trajectories in nephrotic
syndrome.
Study Design: Observational cohort study.
Setting & Participants: Nephrotic Syndrome
Study Network (NEPTUNE) is a multicenter
study of adult and pediatric patients with pro-
teinuria enrolled at clinically indicated kidney bi-
opsy or initial presentation of disease (pediatric
only).
Predictors: Patient demographic, clinical, and pa-
thology variables at study enrollment and follow-up
time.
Outcome: eGFR was calculated using the
Chronic Kidney Disease Epidemiology Collabora-
tion (patients ≥ 18 years old) or modified Chronic
Kidney Disease in Children Study–Schwartz
(patients < 18 years) formulas. The probability of
nonlinearity (PNL) was calculated for individual
eGFR trajectories.Kidney Med Vol 2 | Iss 4 | July/August 2020Analytical Approach: Associations between pre-
dictors and PNL were assessed using multivariable
linear regression.
Results: 453 patients with ≥3 eGFR measure-
ments and 1 or more year of follow-up were
included (median follow-up, 3.6 years). Median
PNL was 0.052; 56% and 16% had PNL < 10%
and >50%, respectively. In both adults and
pediatric patients, higher baseline eGFR was
associated with higher PNL, whereas longer
follow-up time was associated with lower PNL.
Higher urine protein-creatinine ratio and steroid
use were also associated with higher PNL in
adults. Higher percentages of tubular atrophy and
foot-process effacement were associated with
lower and higher PNLs, respectively, in adults.
Limitations: Relatively short follow-up time, inability to
assess acute kidney injury events, and variable eGFR
measurement frequency across patients.
Conclusions: Although increasing follow-up time
resulted in more linear trajectories, nonlinear eGFR
trajectories were common in this cohort. Future
studies in nephrotic syndrome should consider novel
outcomes that do not rely on linearity assumptions.Several chronic kidney disease (CKD) populationscontain subgroups of patients who experience
nonlinear estimated glomerular filtration rate (eGFR) tra-
jectories, with wide variability in reported prevalences of
nonlinearity, including 5% in the hospital-based Neph-
roTest cohort, 10% of Veterans Affairs Healthcare System
patients with CKD stage 4, 15% to 20% in patients with
CKD from 6 clinical trials, and 66% of patients in the
African American Study of Kidney Disease and Hyperten-
sion (AASK).1–4 However, none of these studies assessed
nonlinear eGFR trajectories among patients with glomer-
ular disease, so the prevalence in this population remains
unknown.
Studies of rare glomerular disease are often chal-
lenged by small sample sizes and low rates of clinical
end point occurrence, making novel treatment discovery
especially challenging and the use of surrogate eGFR-
based outcomes especially appealing. However, disease
activity, as well as the medications used to treat
glomerular disease, can cause abrupt changes in eGFRs.
Given these and other unique characteristics of patients
with glomerular disease, our objective was tocharacterize the prevalence of nonlinear eGFR trajec-
tories in the Nephrotic Syndrome Study Network
(NEPTUNE), an incident glomerular disease cohort. In
addition, we sought to identify demographic, clinical,
and pathology predictors of nonlinearity.METHODS
Study Design and Patient Population
NEPTUNE is an ongoing multicenter prospective observa-
tional cohort study of adult and pediatric patients with
proteinuria at screening with protein excretion > 0.5 g/
d (>1.5 g/d in the second study phase).5 Patients were
enrolled at the time of a clinically indicated first kidney
biopsy or initial presentation of disease for pediatric patients
without biopsy. Patients were included in the study if their
biopsy-confirmed diagnosis or clinical diagnosis without
biopsy was minimal change disease, focal segmental glo-
merulosclerosis (FSGS), or membranous nephropathy.
Although not one of the primary glomerular diseases of
interest in NEPTUNE, patients with other diagnoses (pri-
marily immunoglobulin A nephropathy or lupus) who had407
PLAIN-LANGUAGE SUMMARY
Kidney function decline is often assumed to occur at a
constant rate; however, this may not always be the case
in patients with glomerular disease. Using data from the
Nephrotic Syndrome Study Network (NEPTUNE), we
explored participants’ estimated glomerular filtration
rate (eGFR) trajectories and found that about half
exhibited some nonlinear changes over time. Adult
participants with higher baseline eGFR and urine
protein-creatinine ratio values and steroid use at base-
line were more likely to have nonlinear disease pro-
gression, as were those with less tubular atrophy and
more foot-process effacement. Longer follow-up time
was associated with more linear trajectories; however,
shorter-term studies that assess kidney disease pro-
gression in this population should consider end points
that do not rely on constant kidney function decline.
Smith et al.been retained for follow-up in NEPTUNE as a relevant
comparison cohort were also included in this study.
All patients enrolled in the NEPTUNE study provided
informed consent. This study received institutional review
board approval under IRBMED #HUM00026609.
Probability of Nonlinearity in eGFR Outcome
The current study included patients with at least 3 eGFR
measurements in 3 separate months and at least 1 year of
total follow-up. eGFR was calculated using the CKD
Epidemiology Collaboration (CKD-EPI) formula for patients
older than 26 years and the modified Chronic Kidney Dis-
ease in Children Study (CKiD)-Schwartz formula for patients
younger than 18 years, with the average of both formulas
used for patients aged between 18 and 26 years.6 All
available serum creatinine measurements were used, which
includes measurements taken between visits and recorded in
the patient medical record, in addition to those measured
during NEPTUNE study visits. Measurements in the same
month were averaged, and patients were censored if they
progressed to end-stage kidney disease (ESKD).
We used a Bayesian penalized spline regression model
developed by Crainiceanu et al7 and modified by Li et al1
for eGFR trajectories. The model was fit to all available
eGFR measurements for each patient individually as a
function of follow-up time with knots at midpoints be-
tween observation times. The algorithm produced 3,000
smoothed eGFR trajectories that could have produced the
patient’s observed eGFR measurements. Based on the
approach described by Li et al1 for application to eGFR
trajectories in AASK and subsequently used by others,4 a
probability of nonlinearity (PNL) was estimated by the
percentage of trajectories of 3,000 that showed designated
deviations from linearity (see Li et al1 for full technical
details). The algorithm produces numerous possible eGFR408trajectories; therefore, PNL captures the uncertainty in the
true underlying trajectory’s shape. With this method, even
patients with limited numbers of observed eGFR mea-
surements can be included in the analysis, albeit with
greater variability in their possible trajectories.
To describe changes in trajectory as individuals accrued
follow-up time, the PNL for each patient was also calcu-
lated sequentially based on eGFR measurements in the first
year of follow-up, in the first 2 years of follow-up, etc, up
to using the first 5 or more years of follow-up. Each in-
terval included only patients with follow-up through the
end of the interval and a minimum of 3 measurements
during the interval.
Independent Variables
Patient demographics, clinical variables, morphologic
characteristics, and follow-up time were used to predict
PNL. Demographic factors included age, sex, race, and
ethnicity. Baseline clinical characteristics included disease
diagnosis (minimal change disease, membranous ne-
phropathy, FSGS, or other), eGFR (parameterized as a linear
spline with a knot at eGFR of 120 mL/min/1.73 m2, which
may suggest hyperfiltration), urine protein-creatinine ratio
(UPCR), and use of steroids, renin-angiotensin-aldosterone
system inhibitors (RAASis), calcineurin inhibitors, and di-
uretics. Having a high eGFR and medication use during
follow-up were also compared with PNL in descriptive
analyses. Morphologic characteristics from biopsy assess-
ment through the NEPTUNE Digital Pathology Scoring
System8 included interstitial fibrosis (IF), tubular atrophy
(TA), global sclerosis, and foot-process effacement.
Statistical Analysis
Independent variables were summarized using means and
standard deviations for continuous variables and fre-
quencies and percentages for categorical variables. The
distribution of PNL was summarized within patient sub-
groups using median and interquartile range (IQR) and by
frequencies and percentages of patients with <10%, 10%
to 50%, and >50% PNL. PNL by years of follow-up (ie,
first 1, 2, 3, 4, or 5+ years) was compared within sub-
groups. To assess whether the frequency of measurements
was driving linearity, PNL by years of follow-up was also
stratified by number of eGFR measurements available.
Further descriptive analyses compared PNL by medication
use and having high eGFR during follow-up.
Associations between PNL and baseline characteristics
were estimated using multivariable linear regression
models separately for pediatric and adult patients based on
complete-case analyses. PNL was log-transformed for
regression models due to its right-skewed distribution.
Models excluding and including pathology variables were
fitted because these variables were available among only a
subset of patients. We hypothesized that the association
between baseline eGFR and PNL may differ at low or high
eGFRs; therefore, a linear spline was tested. EstimatedKidney Med Vol 2 | Iss 4 | July/August 2020
Table 1. Sample Baseline Characteristics by Disease Cohort
Overall (n = 453) FSGS (n = 148) MCD (n = 139) MN (n = 80) Other (n = 86)
Age, y 32.9 (22.5) 33.8 (21.8) 20.1 (19.3) 51.6 (14.1) 34.8 (21.8)
<18 170 (37.5%) 56 (37.8%) 89 (64.0%) 1 (1.3%) 24 (27.9%)
Sex
Female 183 (40.4%) 51 (34.5%) 68 (48.9%) 31 (38.8%) 33 (38.4%)
Male 270 (59.6%) 97 (65.5%) 71 (51.1%) 49 (61.3%) 53 (61.6%)
Race
White 253 (56.3%) 74 (50.3%) 74 (53.2%) 60 (75.0%) 45 (54.2%)
Black 116 (25.8%) 55 (37.4%) 34 (24.5%) 11 (13.8%) 16 (19.3%)
Other 80 (17.8%) 18 (12.2%) 31 (22.3%) 9 (11.3%) 22 (26.5%)
Hispanic 90 (19.9%) 32 (21.6%) 26 (18.7%) 14 (17.5%) 18 (20.9%)
Baseline eGFR, mL/min/1.73 m2 84.8 (40.8) 73.8 (32.7) 106.1 (50.6) 81.0 (28.0) 73.0 (31.8)
eGFR ≤ 60 128 (28.3%) 62 (41.9%) 15 (10.8%) 18 (22.5%) 33 (38.4%)
eGFR of 60-120 269 (59.4%) 74 (50.0%) 93 (66.9%) 55 (68.8%) 47 (54.7%)
eGFR > 120 56 (12.4%) 12 (8.1%) 31 (22.3%) 7 (8.8%) 6 (7.0%)
Baseline UPCR, mg/mg 2.2 [0.7-4.5] 2.4 [0.9-4.4] 0.9 [0.1-4.0] 4.1 [2.7-7.6] 1.4 [0.6-2.9]
UPCR 0-0.3 73 (16.6%) 12 (8.3%) 48 (36.6%) 0 (0.0%) 13 (15.1%)
UPCR 0.3-1.0 72 (16.3%) 27 (18.8%) 22 (16.8%) 8 (10.0%) 15 (17.4%)
UPCR 1.0-3.0 121 (27.4%) 45 (31.3%) 22 (16.8%) 15 (18.8%) 39 (45.3%)
UPCR > 3.0 175 (39.7%) 60 (41.7%) 39 (29.8%) 57 (71.3%) 19 (22.1%)
Baseline medication
use (multiple possible)
Steroids 161 (35.5%) 39 (26.4%) 87 (62.6%) 9 (11.3%) 26 (30.2%)
RAASi 212 (46.8%) 75 (50.7%) 37 (26.6%) 50 (62.5%) 50 (58.1%)
CNI 41 (9.1%) 11 (7.4%) 21 (15.1%) 4 (5.0%) 5 (5.8%)
Diuretics 151 (33.3%) 42 (28.4%) 41 (29.5%) 45 (56.3%) 23 (26.7%)
Days from biopsy to baseline 19.0 [8.0-31.5] 16.0 [8.0-27.0] 17.0 [7.0-35.0] 17.0 [10.5-27.0] 22.0 [14.0-32.0]
Follow-up time, mo 3.6 [2.1-4.6] 4.1 [2.5-4.6] 3.6 [2.1-4.5] 4.0 [2.3-4.6] 2.5 [1.8-3.6]
Pathology
% Interstitial fibrosis 5.0 [1.0-20.0] 16.0 [3.0-27.0] 1.0 [0.0-4.0] 7.0 [4.0-12.0] 21.0 [9.5-35.0]
% Tubular atrophy 5.0 [0.0-16.0] 13.0 [3.0-25.0] 0.0 [0.0-2.0] 6.0 [3.0-11.0] 21.0 [8.0-34.5]
% Global sclerosis 3.3 [0.0-17.9] 9.0 [0.0-32.7] 0.0 [0.0-3.6] — 4.9 [0.0-33.3]
Foot-process effacement
0%-10% 16 (6.2%) 4 (3.5%) 12 (12.8%) 0 (0%) 0 (0%)
11%-25% 29 (11.2%) 13 (11.3%) 13 (13.8%) 1 (2.3%) 2 (28.6%)
26%-50% 29 (11.2%) 18 (15.7%) 10 (10.6%) 0 (0%) 1 (14.3%)
51%-75% 43 (16.5%) 23 (20.0%) 11 (11.7%) 7 (15.9%) 2 (28.6%)
76%-100% 143 (55.0%) 57 (49.6%) 48 (51.1%) 36 (81.8%) 2 (28.6%)
Note: Values for categorical variables are given as percentages; values for continuous variables are given as mean (standard deviation) or median [interquartile range].
Missingness: race, <1%; ethnicity, <1%; baseline UPCR, <5%; interstitial fibrosis, tubular atrophy, 30.3%; % global sclerosis, 53.9%; foot-process effacement, 38.9%.
Abbreviations: CNI, calcineurin inhibitor; eGFR, estimated glomerular filtration rate; FSGS, focal segmental glomerulosclerosis; MCD, minimal change disease; MN,
membranous nephropathy; RAASi, renin-angiotensin-aldosterone system inhibitor; UPCR, urinary protein-creatinine ratio.
Smith et al.regression coefficients were exponentiated and are pre-
sented as percentage difference in PNL per unit increase in
continuous predictors or percentage difference between
groups for categorical predictors.
Estimation of PNL was conducted in R, version 3.5.1 (R
Core Team), and all other analyses were conducted in SAS,
version 9.4 (SAS Institute Inc).RESULTS
Sample Characteristics
Of 1,033 enrolled NEPTUNE patients, 312 were deemed
ineligible for the NEPTUNE study after enrollment and anKidney Med Vol 2 | Iss 4 | July/August 2020additional 268 were excluded from the current study due
to having less than 1 year of follow-up (n = 145), having
fewer than 3 eGFR measurements (n = 6), or missing
disease diagnosis (n = 106) or baseline eGFR (n = 11; Fig
S1). A total of n = 453 NEPTUNE patients with a median of
11 (range, 3-32) eGFR measurements over a median
follow-up of 3.6 years were included in the current study.
More than half had FSGS or minimal change disease (n =
148 and n = 139, respectively) and n = 80 had mem-
branous nephropathy (Table 1). Nearly two-thirds of pa-
tients were at least 18 years old at baseline, 60% were
male, 56% were white, and 26% were black. Mean eGFR at
baseline in the sample was 84.8 mL/min/1.73 m2 and409
Figure 1. Smoothed estimated glomerular filtration rate (eGFR) trajectories for 4 example patients. The black line represents the
mean estimated eGFR trajectory based on 3,000 smoothed trajectories (with 95% pointwise credible intervals represented by
the gray shaded area) from a Bayesian penalized spline regression model that could have produced the patient’s observed
eGFR measurements (dots). Abbreviation: PNL, probability of nonlinearity.
Smith et al.median UPCR at baseline was 2.2 mg/mg. About one-
third of patients were taking steroids or diuretics at base-
line, almost half (47%) were using RAASis, and 9% were
using a calcineurin inhibitor.
Distribution of PNL
Figure 1 shows several examples of smoothed eGFR tra-
jectories for low and high PNLs. The sample median PNL
was 0.052 (IQR, 0.0023-0.292), with 253 (56%) having
PNL < 10% and 71 (16%) having PNL > 50%. Adult pa-
tients and those with lower baseline eGFRs had lower410PNLs, indicating more linear eGFR trajectories among
these subgroups (Table 2). Hispanic patients and those
taking steroids or RAASis at baseline had higher PNLs,
indicating more nonlinear eGFR trajectories among these
subgroups.
Predictors of PNL
Multivariable models without pathology variables were
fitted for 278 adults and 149 pediatric patients. In adults,
FSGS and other disease cohorts and longer follow-up time
were associated with lower PNLs, whereas higher UPCRsKidney Med Vol 2 | Iss 4 | July/August 2020
Table 2. Distribution of PNL by Baseline Subgroups and Follow-up Time
Overall PNL PNL < 10% PNL 10%-50% PNL > 50%
Age, y
<18 0.24 [0.05-0.56] 54 (31.8%) 67 (39.4%) 49 (28.8%)
≥18 0.01 [0.00-0.12] 199 (70.3%) 62 (21.9%) 22 (7.8%)
Sex
Female 0.05 [0.00-0.27] 105 (57.4%) 55 (30.1%) 23 (12.6%)
Male 0.05 [0.00-0.30] 148 (54.8%) 74 (27.4%) 48 (17.8%)
Race
White 0.03 [0.00-0.21] 155 (61.3%) 67 (26.5%) 31 (12.3%)
Black 0.09 [0.00-0.35] 62 (53.4%) 35 (30.2%) 19 (16.4%)
Other 0.12 [0.00-0.49] 36 (45.0%) 25 (31.3%) 19 (23.8%)
Ethnicity
Hispanic 0.11 [0.01-0.43] 42 (46.7%) 30 (33.3%) 18 (20.0%)
Non-Hispanic 0.04 [0.00-0.27] 210 (58.5%) 98 (27.3%) 51 (14.2%)
Diagnosis
FSGS 0.03 [0.00-0.14] 50 (62.5%) 23 (28.8%) 7 (8.8%)
MCD 0.17 [0.04-0.47] 52 (37.4%) 54 (38.8%) 33 (23.7%)
MN 0.01 [0.00-0.26] 52 (60.5%) 24 (27.9%) 10 (11.6%)
Other 0.01 [0.00-0.18] 99 (66.9%) 28 (18.9%) 21 (14.2%)
Baseline eGFR, mL/min/1.73 m2
≤60 0.00 [0.00-0.10] 96 (75.0%) 24 (18.8%) 8 (6.3%)
60-120 0.07 [0.01-0.30] 145 (53.9%) 78 (29.0%) 46 (17.1%)
>120 0.37 [0.13-0.56] 12 (21.4%) 27 (48.2%) 17 (30.4%)
Baseline UPCR, mg/mg
0-0.3 0.08 [0.01-0.23] 41 (56.2%) 18 (24.7%) 14 (19.2%)
0.3-1.0 0.05 [0.00-0.26] 44 (61.1%) 18 (25.0%) 10 (13.9%)
1.0-3.0 0.01 [0.00-0.14] 83 (68.6%) 30 (24.8%) 8 (6.6%)
>3.0 0.11 [0.01-0.39] 84 (48.0%) 56 (32.0%) 35 (20.0%)
Baseline medication use
Steroids 0.17 [0.03-0.49] 64 (39.8%) 57 (35.4%) 40 (24.8%)
RAASi 0.02 [0.00-0.19] 130 (61.3%) 60 (28.3%) 22 (10.4%)
CNI 0.27 [0.05-0.60] 12 (29.3%) 12 (29.3%) 17 (41.5%)
Diuretics 0.03 [0.00-0.24] 88 (58.3%) 42 (27.8%) 21 (13.9%)
Follow-up duration
1 y 0.28 [0.09-0.58] 24 (25.0%) 42 (43.8%) 30 (31.3%)
2 y 0.11 [0.01-0.45] 45 (46.4%) 32 (33.0%) 20 (20.6%)
3 y 0.04 [0.00-0.16] 47 (62.7%) 20 (26.7%) 8 (10.7%)
4 y 0.01 [0.00-0.12] 123 (72.4%) 35 (20.6%) 12 (7.1%)
5 y 0.00 [0.00-0.04] 14 (93.3%) 0 (0%) 1 (6.7%)
Note: Values for categorical variables are given as percentages; values for continuous variables are given as median [interquartile range].
Abbreviations: CNI, calcineurin inhibitor; eGFR, estimated glomerular filtration rate; FSGS, focal segmental glomerulosclerosis; MCD, minimal change disease; MN,
membranous nephropathy; PNL, probability of nonlinearity; RAASi, renin-angiotensin-aldosterone system inhibitor; UPCR, urinary protein-creatinine ratio.
Smith et al.and steroid use at baseline were associated with higher
PNLs (Table 3, full sample). Higher baseline eGFR was
associated with higher PNL, but the magnitude of this
effect was substantially higher for patients with baseline
eGFRs > 120 mL/min/1.73 m2 (+102%; 95% confidence
interval [CI], +37% to +198%; P < 0.01 for eGFRs > 120
vs +6%; 95% CI, +1% to +13%; P = 0.03 for eGFRs ≤
120 mL/min/1.73 m2; see Fig S2a for graphical illustra-
tion). For pediatric patients, longer follow-up time was
associated with lower PNLs, whereas higher baseline
eGFRs were associated with higher PNLs, but only for
those with baseline eGFRs ≤ 120 mL/min/1.73 m2
(Table 4, full sample; Fig S2b).Kidney Med Vol 2 | Iss 4 | July/August 2020IF, TA, and global sclerosis were highly correlated (Pear-
son correlations between 0.70 and 0.99), so these features
were tested separately along with the clinical predictors and
foot-process effacement in the subset of patients with pa-
thology data (n = 149 adults, n = 100 pediatric patients).
Although all 3 glomerular/tubulointerstitial features yielded
similar R2 values (R2 adult/pediatric = 0.495/0.270 for TA
model vs 0.485/0.302 for IF model and 0.490/0.265 for
global sclerosismodel), the TAmodelwas chosen for the final
adult model and the IF model was chosen for the final pedi-
atric model because they demonstrated the best model fit.
Adjusted for TA and foot-process effacement, older age
and longer follow-up were associated with lower PNL,411
Table 3. Baseline Clinical Predictors of PNL of eGFR Trajectories Based on Multivariable Linear Regression Models of log(PNL)
Among Adult Patients
Predictor
Full Sample (n = 278) Pathology Subsample (n = 149)
% Difference
in PNL 95% CI P
% Difference
in PNL 95% CI P
Age, per 10 y +1% −8% to +11% 0.85 −12% −23% to −0% 0.04
Male sex (ref: female sex) +29% −3% to +71% 0.07 +57% +10% to +123% 0.01
Black race (ref: all other races) +14% −19% to +63% 0.45 +28% −18% to +99% 0.27
Hispanic (ref: non-Hispanic) −2% −33% to +41% 0.90 +14% −26% to +77% 0.55
Diagnosis (ref: MCD)
MN −24% −51% to +18% 0.22 −25% −56% to +25% 0.26
FSGS −50% −67% to −22% <0.01 −37% −61% to +3% 0.06
Other −60% −75% to −37% <0.01 −50% −85% to +68% 0.26
Follow-up time, per y −45% −50% to −39% <0.01 −41% −49% to −32% <0.01
Baseline eGFR, per 10 mL/min/1.7
3 m2 for eGFR ≤ 120
+6% +1% to +13% 0.03 −6% −14% to +2% 0.14
Baseline eGFR, per 10 mL/min/
1.73 m2 for eGFR > 120
+102% +37% to +198% <0.01 +145% +71% to +251% <0.01
Baseline UPCR, per mg/mg +5% +1% to +8% <0.01 +3% −1% to +8% 0.16
Baseline steroid use +50% +6% to +113% 0.02 +27% −20% to +102% 0.30
Baseline CNI use −23% −66% to +74% 0.53 +71% −38% to +370% 0.30
Baseline RAASi use +3% −22% to +36% 0.85 +10% −23% to +56% 0.60
Baseline diuretic use +7% −20% to +42% 0.66 −14% −41% to +25% 0.44
Tubular atrophy, per 10% — — — −20% −30% to −9% <0.01
Foot-process effacement, per unit
increase in ordinal scalea
— — — +21% +3% to +41% 0.02
Note: Coefficients (beta) were transformed to 100×[exp(beta) − 1] to represent percentage change in PNL. Negative percent differences in PNL indicate more linear
eGFR trajectories for a 1-unit increase in continuous variables or difference between groups for categorical variables, whereas positive percent differences in PNL
indicate more nonlinear eGFR trajectories. R2 for full sample model was 0.42 and for pathology subsample model was 0.49.
Abbreviations: CI, confidence interval; CNI, calcineurin inhibitor; eGFR, estimated glomerular filtration rate; FSGS, focal segmental glomerulosclerosis; MCD, minimal
change disease; MN, membranous nephropathy; PNL, probability of nonlinearity; RAASi, renin-angiotensin-aldosterone system inhibitor; ref, reference; UPCR, urinary
protein-creatinine ratio.
aFoot-process effacement was recorded on an ordinal scale with 0 corresponding to 0% to 10% of the glomerular capillary surface area affected by effacement, 1 =
11% to 25%, 2 = 26% to 50%, 3 = 51% to 75%, and 4 = 76% to 100%.
Smith et al.whereas male sex and higher eGFR at baseline for patients
with baseline eGFRs > 120 mL/min/1.73 m2 were asso-
ciated with higher PNL in adults (Table 3, pathology
subsample). TA was associated with lower PNL (−20% per
10% increase in TA; 95% CI, −30% to −9%), whereas foot-
process effacement was associated with higher PNL (+21%
per unit increase in ordinal scale; 95% CI, +3%-+41%). In
pediatric patients, longer follow-up time was associated
with lower PNL, and neither IF nor foot-process efface-
ment were associated with PNL (Table 4, pathology
subsample).
PNL Over Follow-up Time
As follow-up time increased, PNL decreased on average.
This trend of increased linear trajectory over time was also
apparent among patient subgroups by age, black versus
nonblack race, eGFR, and UPCR (Fig 2). The differences in
PNL between pediatric and adult subgroups and between
black and nonblack patients were sustained throughout
different follow-up times. However, although patients
with baseline eGFRs ≤ 60 mL/min/1.73 m2 had much
lower PNLs than those with baseline eGFRs > 60 mL/min/
1.73 m2 in the first year of follow-up, patients with
baseline eGFRs ≤ 60 and those with 60 < eGFR ≤ 120 mL/412min/1.73 m2 had similarly low PNLs when including 5 or
more years of follow-up. Furthermore, PNLs differed by
baseline UPCR in the first year of follow-up but were low
across all levels of baseline UPCR when including 5 or
more years of follow-up. Although PNL was lower for
patients with longer follow-up overall (Fig S3), the dis-
tributions of PNL within a given amount of follow-up was
largely overlapping for varying numbers of eGFR mea-
surements, indicating that lower PNL was not systemati-
cally driven by having more eGFR measurements available
(Fig 3).
Patients who had high eGFRs (ie, eGFRs > 120 mL/
min/1.73 m2) during follow-up or those who
used calcineurin inhibitors or steroids at least once during
follow-up had higher PNLs (Fig 4) despite similar median
follow-up times. Conversely, patients who had ever used
diuretics or RAASis had similar or lower PNLs than those
who had never used diuretics or RAASis during follow-up.
Follow-up time was similar for patients who ever versus
never used diuretics, but patients who ever used RAASis
had a longer median follow-up time compared with those
who never used RAASis (43 vs 31 months).
Rates of progression to ESKD or 40% decline in eGFR
across categories of PNL (<10%, 10%-50%, and >50%)Kidney Med Vol 2 | Iss 4 | July/August 2020
Table 4. Baseline Clinical Predictors of PNL of eGFR Trajectories Based on Multivariable Linear Regression Models of log(PNL)
Among Pediatric Patients
Predictor
Full Sample (n = 155) Pathology Subsample (n = 100)
% Difference
in PNL 95% CI P
% Difference
in PNL 95% CI P
Age, per 10 y −23% −51% to +20% 0.25 −29% −61% to +31% 0.27
Male sex (ref: female sex) +22% −16% to +75% 0.29 +10% −34% to +84% 0.71
Black race (ref: all other races) +7% −29% to +60% 0.75 +11% −35% to +90% 0.70
Hispanic (ref: non-Hispanic) +43% −8% to +122% 0.11 +18% −33% to +108% 0.57
Diagnosis (ref: MCD)
FSGS −27% −53% to +13% 0.16 −31% −61% to +23% 0.21
Other −25% −57% to +30% 0.30 +14% −73% to +383% 0.86
Follow-up time, per y −32% −42% to −21% <0.01 −31% −45% to −13% <0.01
Baseline eGFR, per 10 mL/min/
1.73 m2 for eGFR ≤ 120
+18% +7% to +31% <0.01 +12% −4% to +30% 0.15
Baseline eGFR, per 10 mL/min/
1.73 m2 for eGFR>120
+2% −4% to +8% 0.51 +1% −9% to +13% 0.80
Baseline UPCR, per mg/mg +2% −1% to +4% 0.15 +2% −1% to +6% 0.24
Baseline steroid use −5% −37% to +43% 0.80 −34% −62% to +14% 0.14
Baseline CNI use +33% −16% to +111% 0.23 +20% −32% to +114% 0.52
Baseline RAASi use +12% −26% to +68% 0.59 +37% −23% to +142% 0.28
Baseline diuretic use −15% −49% to +45% 0.56 −18% −60% to +70% 0.59
Interstitial fibrosis, per 10% — — — −8% −28% to +18% 0.52
Foot-process effacement, per unit
increase in ordinal scalea
— — — +6% −12% to +28% 0.52
Note: Coefficients (beta) were transformed to 100×[exp(beta) − 1] to represent percentage change in PNL. Negative percent differences in PNL indicate more linear
eGFR trajectories for a 1-unit increase in continuous variables or difference between groups for categorical variables, whereas positive percent differences in PNL
indicate more nonlinear eGFR trajectories. R2 for full sample model was 0.34 and for pathology subsample model was 0.30.
Abbreviations: CI, confidence interval; CNI, calcineurin inhibitor; eGFR, estimated glomerular filtration rate; FSGS, focal segmental glomerulosclerosis; MCD, minimal
change disease; PNL, probability of nonlinearity; RAASi, renin-angiotensin-aldosterone system inhibitor; UPCR, urinary protein-creatinine ratio.
aFoot-process effacement was recorded on an ordinal scale with 0 corresponding to 0% to 10% of the glomerular capillary surface area affected by effacement, 1 =
11% to 25%, 2 = 26% to 50%, 3 = 51% to 75%, and 4 = 76% to 100%.
Smith et al.showed somewhat higher event rates for PNLs > 50%
compared with PNLs < 10% or 10% to 50% (13.7 per
1,000 person-months vs 6.6-9.2 per 1,000 person-
months; Table S1). These rates were similar when assess-
ing PNLs within the first year, first 2 years, etc. Linear
eGFR slope per month was also steeper overall for patients
with PNLs > 50% (−0.53 per month vs −0.24 to −0.43 per
month).DISCUSSION
A nontrivial minority of patients with glomerular disease
in our study exhibited nonlinearity in their eGFR trajec-
tories, with 17% having PNLs > 50%. This result is similar
to the prevalence of nonlinearity observed in nondiabetic
patients with CKD from clinical trials.4 Pediatric patients
were more likely to have nonlinear eGFR trajectories, as
were adults with minimal change disease, higher UPCRs
and eGFRs at baseline, and more foot-process effacement,
whereas adults with more TA had more linear eGFR tra-
jectories. Relationships between PNL and age, sex, and
eGFR are consistent with other studies that used similar
methodology to calculate PNL.1,4
As a whole, patients with characteristics consistent with
increased disease activity and current immunosuppressiveKidney Med Vol 2 | Iss 4 | July/August 2020treatment were more likely to have nonlinear trajectories.
This could have several underlying mechanisms, such as
fluid shifts, medication changes, and measurement error in
eGFR, as well as transient morphologic changes such as
foot-process effacement. For example, because use of
RAASi has a hemodynamic effect and was hypothesized to
be associated with higher PNLs, it may be that our finding
of lower PNLs with RAASi use is due to confounding by
indication, that is, clinicians are more likely to use this
medication when patients have achieved a more stable
trajectory. Conversely, those with evidence of chronic
scarring, lower disease activity, and low eGFRs were more
likely to have linear trajectories. However, due to the
observational nature of the study and potential con-
founding by indication, we are unable to assign causality
to any factors associated with PNL, particularly related to
medication use.
We also found that eGFR trajectories were more
linear after observing patients for longer follow-up
times. Although a previous study emphasized that
more follow-up could be associated with more nonlin-
earity due to increased opportunity to detect nonline-
arity,4 there are several differences in study
characteristics. First, our sample was composed of newly
diagnosed pediatric patients and patients with nephrotic413
Figure 2. Median probability of nonlinearity (PNL) by year from baseline and (top left) age, (top right) race, (bottom left) baseline
estimated glomerular filtration rate (eGFR), and (bottom right) baseline urinary protein-creatinine ratio (UPCR). Note that patients
contribute to median PNL estimates for multiple years from baseline up to their maximum observed follow-up time.
Smith et al.syndrome enrolled at the time of kidney biopsy, whose
disease activity and medication changes shortly after
study enrollment may have been more variable
compared with later times in follow-up or compared
with more stable prevalent patients. This is a relevant
population for determining optimal surrogate outcomes
for clinical research studies because identifying predic-
tive biomarkers at the time of disease onset or biopsy is
critical to informing therapeutic choices.
Second, our study of nephrotic patients may have
different disease progression trajectories compared with
general patients with CKD due to the interaction between
high-grade proteinuria and kidney function.
Third, the frequency of high eGFR events, which we
found to be associated with nonlinearity, may be more
common at the beginning of follow-up in incident
nephrotic patients.
Lastly, because nephrotic syndrome is a relapsing and
remitting disease and our results showed decreasing
UPCRs over time on average, the impact of follow-up time
on PNL differs from more common kidney diseases such as
diabetic nephropathy.414Although we demonstrated that the likelihood of
nonlinear eGFR is low 4 or 5 years after disease onset,
clinical trials are not always limited to incident patients
and rarely will include more than 2 years of follow-up.
Although this was an observational study demonstrating
patterns of nonlinearity under usual clinical care with
medication cessation and initiation that would not
occur in a clinical trial, our preliminary assessment of
eGFR slope by PNL categories for varying follow-up
periods demonstrated that the timing of assessment of
nonlinearity may affect the calculation of traditional
surrogate outcomes for ESKD. Therefore, shorter-term
studies examining changes in eGFR will likely be
affected by nonlinear eGFR trajectories. This is partic-
ularly true if target populations include patients with
characteristics more likely to present with these trajec-
tories. Furthermore, our preliminary finding of higher
rates of progression to ESKD or 40% decline in eGFR
among those with more nonlinear eGFR trajectories
calls into question the suitability of percentage eGFR
decline outcomes in the presence of nonlinearity.
Future research is thus underway to determine optimalKidney Med Vol 2 | Iss 4 | July/August 2020
Figure 3. Distribution of probability of nonlinearity (PNL) grouped by years from baseline for varying numbers of estimated glomerular
filtration rate (eGFR) measurements across follow-up time. Note that patients contribute to median PNL estimates for multiple years
from baseline up to their maximum observed follow-up time. Each box represents the interquartile range (IQR; 25th-75th percentile)
of the PNL distribution, with horizontal line at the median and symbol within the box representing the mean. Whiskers represent the
range of observations within 1.5×IQR from the box and symbols represent outlier observations.
Smith et al.methods for accounting for nonlinearity in surrogate
CKD progression outcomes.
Our study has several strengths, including the appli-
cation of a novel method for quantification of nonline-
arity of eGFR trajectories to patients with glomerular
disease.1 Another commonly used method, latent class
mixed models, fits linear mixed models to the observed
eGFR measurements, which can be noisy due to mis-
measurement of serum creatinine, estimation bias, and
short-term biological variation. The smoothing method
applied in our report addresses these issues by resam-
pling, which allows for estimation of the uncertainty
regarding the true trajectory given the variation in the
observed measures.1 Our study also included a large
proportion of pediatric patients, among whom research
in eGFR trajectories has been sparse. Finally, we consid-
ered several data domains from the NEPTUNE study to
assess predictors of nonlinearity, including not only de-
mographics and clinical characteristics but also pathology
data.
However, our study is not without limitations.
Follow-up time was relatively short, with a median
follow-up of 3.6 (IQR, 2.1-4.6; range, 1.1-6.2) years.
Despite this, we were able to detect nonlinear trajec-
tories in this cohort that would likely be representative
of a population of newly diagnosed patients undergoingKidney Med Vol 2 | Iss 4 | July/August 2020usual clinical care. That said, the prevalence of nonlinear
trajectories should be confirmed in other glomerular
disease cohorts. The 1-year minimum follow-up
requirement prevented us from assessing PNL in pa-
tients with rapid early declines to ESKD. In addition, the
study cohort combined patients with multiple types of
glomerulonephritis whose outcomes are varied, and
some subgroup comparisons may be underpowered.
Therefore, relationships between PNL and clinical char-
acteristics and outcomes need to be verified in larger
more homogeneous cohorts. Another limitation was our
inability to assess the effect of acute kidney injury events
on PNL because this information was not collected
directly and serum creatinine measurements were not
frequent enough to detect these events based on KDIGO
(Kidney Disease: Improving Global Outcomes) guide-
lines. It is hypothesized that acute kidney injury events
may increase PNL, and consideration of whether these
events should be considered part of the true eGFR tra-
jectory deserves further consideration.
This study included both protocol-driven and clinically
driven eGFR measurements, and patients with more clin-
ically driven measurements may be experiencing periods
of more active disease. However, we did not observe clear
associations between PNL and number of eGFR measure-
ments in our study. Furthermore, in patients with longer415
Figure 4. Distribution of probability of nonlinearity (PNL) by medication use or incidence of high estimated glomerular filtration rate
(eGFR; >120 mL/min/1.73 m2) at least once between screening and end of follow-up. Each box represents the interquartile range
(IQR; 25th-75th percentile) of the PNL distribution, with horizontal line at the median and symbol within the box representing the
mean. Whiskers represent the range of observations within 1.5×IQR from the box and symbols represent outlier observations. Ab-
breviations: CNI, calcineurin inhibitor; RAASi, renin-angiotensin-aldosterone system inhibitor.
Smith et al.follow-up, we expect that any effect of eGFR frequency
was dampened by longer periods of stable disease, as
demonstrated by lower PNLs with longer follow-up.
Finally, the inclusion of baseline eGFR as a covariate in
PNL models may have resulted in some bias due to mea-
surement error because baseline eGFR was also included in
the calculation of PNL. However, removing it from the
models would likely result in larger biases due to con-
founding. We included baseline eGFR in the calculation of
PNL because for patients with protocol-driven eGFR
measurements only, the change from baseline to the sec-
ond measurement provides important information about
nonlinearity.
Nonlinear eGFR trajectories occur in a subset of patients
with glomerular disease and should be accounted for when
estimating disease progression outcomes and rates of
decline. In studies of patients with glomerular disease with
shorter follow-up times, nonlinear trajectories will be
more prevalent regardless of the number of creatinine
measurements. In addition, medication use and high
eGFRs, which are relatively common, increase PNLs sub-
stantially. Future work that can further elucidate these
different mechanisms and shapes of nonlinearity will be
useful, for example, to understand the timing of nonlin-
earity. Furthermore, there is a need for strategies and novel
statistical methods that account for these events. Recent416methods that calculate time to percentage eGFR decline by
fitting linear regression models to eGFR trajectories
attempt to address the potential error in eGFR; however,
they still cannot accommodate nonlinear trajectories.9
When follow-up is sufficiently long, linear assumptions
for calculating eGFR slope or time to percentage decline
may be appropriate for most patients. However, it will not
be applicable to all, and flexible forms for time (eg,
polynomial terms in regression models) should be
considered when eGFR is used as an outcome in clinical
research.SUPPLEMENTARY MATERIAL
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Figure S1: Enrollment flow chart for the study.
Figure S2: Relationship between baseline eGFR and PNL modeled
as a linear spline in (A) adults and (B) pediatric patients.
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follow-up time.
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